Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer

2008 ◽  
Vol 14 (1) ◽  
pp. 215-223 ◽  
Author(s):  
G. Folprecht ◽  
J. Tabernero ◽  
C.-H. Kohne ◽  
C. Zacharchuk ◽  
L. Paz-Ares ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Receptor Tyrosine Kinase ◽  
Growth Factor Receptor ◽  
Line Treatment ◽  
First Line ◽  
Irreversible Inhibitor ◽  
Epidermal Growth ◽  
First Line Treatment

scholarly journals Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer

Cancer ◽  
2011 ◽  
Vol 118 (6) ◽  
pp. 1523-1532 ◽  
Author(s):  
Fotios Loupakis ◽  
Chiara Cremolini ◽  
Lisa Salvatore ◽  
Marta Schirripa ◽  
Sara Lonardi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Monoclonal Antibodies ◽  
Growth Factor ◽  
Growth Factor Receptor ◽  
Clinical Impact ◽  
Line Treatment ◽  
First Line ◽  
Epidermal Growth ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document